Skip to main content
. Author manuscript; available in PMC: 2010 Nov 1.
Published in final edited form as: Pain. 2009 Sep 12;146(1-2):130–140. doi: 10.1016/j.pain.2009.07.011

Fig. 4.

Fig. 4

SIP30 participates in the maintenance of peripheral nerve injury-induced neuropathic pain. After mechanical allodynia and thermal hyperalgesia were already developed post CCI surgery, antisense oligonucleotide treatment was initiated. Shaded area (marked “i.t.”) indicates intrathecal injection. Upward arrow marked “CCI” indicates the day of CCI surgery. PWT, paw withdrawal threshold; PTL, paw withdrawal latency. Intrathecal injection of SIP30 antisense oligonucleotide (CCI+ASI) for 4 days (from day 3 to day 7 post-CCI) attenuated both mechanical allodynia (a) and thermal hyperalgesia (b) in the CCI ipsilateral paw (“Ipsi.”), but normal saline (CCI+NS) and missense oligonucleotide (CCI+MS) had no effect. *p<0.05 for the SIP30 antisense oligonucleotide group vs. either normal saline or missense oligonucleotide group. (c, d) No significant change was seen in the CCI contralateral paw after the same treatments.